Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride doesn't affect antipyrine metabolism, so interactions with cytochrome P-450 enzyme drugs are unlikely.

This study found that using nanoporous silica entrapped lipid-drug complexes enhanced the solubility and bioavailability of dutasteride in beagle dogs.

This study found that co-administering glucocorticoids with 5α-reductase inhibitors exacerbated the adverse metabolic effects of glucocorticoids in healthy men.

This review discusses post-finasteride syndrome, emphasizing its serious psychological and cognitive symptoms and the need for more research and awareness in the medical community, but provides no new clinical findings.

This study evaluated novel steroid compounds for their ability to inhibit 5α-reductase, showing that compound 16a significantly reduced rat prostate weight more than epristeride and exhibited excellent in vitro inhibitory potency, indicating its potential as a lead candidate for further benign prostatic hyperplasia drug research.

This article reviews the impact of aging and related urologic conditions on male fertility, highlighting the effects of various treatments on sperm parameters and recommending pre-treatment counseling for fertility preservation. It reports no new clinical results.

This study found that the 5α-steroid metabolite profile in men with inherited 5α-reductase deficiency is similar to those taking the drug finasteride, suggesting the gene affects multiple steroid substrates.

This study suggests that in rat skin, testosterone itself may play a more significant role in androgen action than 5α-dihydrotestosterone, unlike in the prostate where 5α-DHT is more dominant.

This study found no evidence that finasteride use is associated with an increased risk of male breast cancer.

This article discusses post-finasteride syndrome as a distinct syndrome related to prolonged use of 5α-steroid reductase inhibitors, noting persistent side effects even after discontinuation and no new research results are reported.

This study found that dutasteride use is associated with increased reports of sexual dysfunction, based on data from the U.S. Food and Drug Administration Adverse Event Reporting System.

This study found that finasteride may reduce inappropriate sexual behaviors in geriatric patients with vascular dementia and benign prostate hyperplasia without serious side effects, though some patients required additional medications.

This review discusses the established efficacy and safety of finasteride and dutasteride for benign prostatic hyperplasia, their use with alpha adrenergic blockers, and the potential unclear role in cancer prevention.

This study found that for men with moderate-to-severe LUTS/BPH, 6 months of treatment with tamsulosin plus the hexanic extract of S. repens was as effective as tamsulosin plus a 5-alpha-reductase inhibitor but had better tolerability.

This review discusses the impact of ACE polymorphism on COVID-19 severity, suggesting it affects adults more than children, but presents mixed findings concerning infection prevalence and mortality.

This study found that among eleven tested polymethoxyflavones, 5-hydroxy-7,4′-dimethoxyflavone was the strongest steroid 5α-reductase inhibitor and suggests potential use for benign prostatic hyperplasia treatment.

This study concluded that Flaxin tablets and the reference formulation are bioequivalent in terms of absorption rate and extent when administered as a single 5 mg dose to healthy male volunteers.

This review discusses medical therapies for benign prostatic hyperplasia, highlighting the importance of personalizing treatments to individual patient needs and preferences.

This study found that red ginseng oil (RXGIN) significantly improved lower urinary tract symptoms and some aspects of sexual function in men, with no serious adverse events reported.

Finasteride use may be linked to rare testicular tumor, but more research needed.

In this study, a new Finasteride conjugate showed stronger inhibition of 5α-reductase and similar reduction of prostate hyperplasia in rats compared to Finasteride, with potentially improved toxicity.

This study suggests that Lygodium japonicum may reduce cell damage and tissue proliferation in a rat model of benign prostatic hyperplasia, indicating potential as a treatment.

This study found no positive association between the use of 5α-reductase inhibitors and the risk of male breast cancer.

This case report describes a 66-year-old male with benign prostatic hyperplasia who developed urinary incontinence after starting venlafaxine, which resolved upon discontinuation of the medication.

This review reports that combination therapy with 5α-reductase inhibitors and α1-receptor blockers does not appear to benefit patients with benign prostatic hyperplasia and prostate volumes up to 40–45 ml, but may be more effective for larger prostate volumes.

The authors concluded that finasteride and dutasteride might have serious side effects, including persistent sexual dysfunction for some, necessitating further research and vigilant risk-benefit analysis.

This study introduced and validated new spectrophotometric methods to simultaneously determine finasteride and tadalafil in Entadfi™ capsules with high sensitivity and without interference from excipients.

This study concluded that dutasteride modestly reduces nocturia in men but does not improve sleep quality.

This study found that coadministration of tadalafil and finasteride improved lower urinary tract symptoms and erectile function in men with benign prostatic hyperplasia better than finasteride alone over 26 weeks.

This review concluded that WS PRO 160 I 120 mg, a herbal preparation, may be an effective and safer alternative to standard drugs for treating lower urinary tract symptoms in men with benign prostatic hyperplasia.